- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
From the Gastrointestinal Cancers Symposium: Statins use may reduce mortality in hepatocellular cancer by 30%
Use of statins in hepatocellular carcinoma (HCC) patients may be associated with prolonged overall survival.
Use of statins in hepatocellular carcinoma (HCC) patients may be associated with prolonged overall survival, according to a poster session presented at the recent Gastrointestinal Cancers Symposium, in San Francisco.
Young Kwang Chae, MD, of the University of Texas MD Anderson Cancer Center in Houston, and colleagues researched the association between statin use and the outcome of patients with HCC.
“There has been observational studies that statins may reduce the risk of hepatocellular carcinoma,” Dr Chae told Formulary. “Also, there is consistent preclinical studies showing anti-tumor effect of statins across different types of cancers.”
In a retrospective survival analysis using single institution data, Dr Chae and colleagues followed 644 patients diagnosed with pathologically confirmed HCC from 2000 to 2011. Survival analysis was done using Cox regression model.
Drop in mortality
In the HCC cohort of patients, those who took statins in addition to local and systemic therapy or surgical resection had a 30% reduction in mortality versus non-statin users (HR=0.7, 95% CI, 0.5-0.9; P=.03).
The mean age of the HCC cohort was aged 63.1 years; 73.4% were men, and 65.5% were Caucasians. Approximately 70% were diagnosed at TNM stage 3 and 4, and 52.6% had no evidence of hepatitis B or C virus infection. More than 80% had local and systemic therapy, while 18.3% underwent surgical resection. The median overall survival of HCC patients was higher among statin users than non-users at 25.4 months versus 18.5 months (P=.04).
“Even after controlling for various clinical variables including age, sex, race, staging, HCV, HBV, liver cirrhosis, treatment, alcohol use and diabetes, statin use was still associated with favorable overall survival in HCC patients,” the researchers wrote.
“We found that among patients without underlying liver cirrhosis the favorable effect of statins on survival was significant,” Dr Chae said.
“Statin use may have beneficial role in patients with hepatocellular carcinoma. However, this finding has to be validated with a prospective study,” Dr Chae concluded. â
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
